COMP <GO>
ALT vs RZLT // EV/EBITDA & P/E VALUATION
Altimmune Inc. (NASDAQ) VS. Rezolute Inc. (NV) (NASDAQ) • 15-METRIC TALLY: ALT 4
— RZLT 1
■ METRIC PARITY
LAST: $2.14 (+1.91%) • MKT CAP: $416.3M
valuation
—
LAST: $4.12 (-2.37%) • MKT CAP: $398.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALT VS. RZLT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALT | RZLT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.70% | -35.00% | +0.30 | ALT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.23% | -17.33% | +1.10 | ALT | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 105.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.30 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 2/9 | +3.00 | ALT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.7 | 45.9 | -19.18 | RZLT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $416.3M | $398.5M | $17.7M | ALT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALT REV | RZLT REV | ALT GROSS % | RZLT GROSS % | ALT FCF | RZLT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $41.0K | $0 | — | — | -$67.5M | -$69.1M |
| FY 2024 | $20.0K | $0 | — | — | -$79.8M | -$57.4M |
| FY 2023 | $426.0K | $0 | — | — | -$75.8M | -$44.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALT // BETA —
RZLT // BETA —